DI-046 Intravitreal bevacizumab vs. laser photocoagulation in retinopathy of prematurity
| Autor: | H Mateo Carrasco, TB Rodríguez Cuadros, P Nieto Guindo, D Fernández Ginés, F Verdejo Reche |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
genetic structures Bevacizumab business.industry Standard treatment Gestational age Retinal detachment Retrospective cohort study Retinopathy of prematurity medicine.disease eye diseases Ophthalmology Cohort medicine lipids (amino acids peptides and proteins) General Pharmacology Toxicology and Pharmaceutics Adverse effect business medicine.drug |
| Zdroj: | European Journal of Hospital Pharmacy. 22:A92.3-A93 |
| ISSN: | 2047-9964 2047-9956 |
| DOI: | 10.1136/ejhpharm-2015-000639.222 |
| Popis: | Background Laser photocoagulation (LPC) is considered the standard treatment for retinopathy of prematurity (ROP), but LPC is destructive, causes complications, and does not prevent all vision loss. Recently, bevacizumab (a vascular endothelial growth factor inhibitor) has been used with po-sitive results. Purpose To evaluate the efficacy and safety of intravitreal bevacizumab vs. LPC in preterm infants with ROP grades 1 to 3+. Material and methods Ten-month retrospective study that included patients with gestational age of less than 30 weeks diagnosed with ROP grades 1 to 3+, and weight Results Twelve patients were included, six for each treatment arm The proportion of females was 50% for the bevacizumab group and 66.6% for the LPC group. Mean gestational age was 25 weeks [23–29] in both groups. Efficacy: CV was achieved in five cases (83.4%) in the bevacizumab arm, and in two patients (33.3%) of those receiving LPC. Safety: no adverse effects were observed in the antiangiogenic treatment arm. In the LPC group, two cases of retinal detachment (inoperable in one case), one of localised reversible haemorrhage, one of retinal fibrosis, and one of laser-related scarring were found. Conclusion In this cohort, intravitreal bevacizumab was more effective and safer than LPC in the treatment of ROP grades 1–3+. This is consistent with previous published studies, and supports the use of the antiangiogenic over LPC in the treatment of ROP. References and/or acknowledgements Dr Hector Mateo No conflict of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|